토토 카지노

The upcoming KOSDAQ listing of 토토 카지노 marks the completion of Phase 1 in the company’s growth journey, with plans to achieve .1 million in annual sales from rare disease genetic diagnostics within five years. In an interview with Hit News, CEO Changwon Geum shared these ambitious goals for the AI-driven diagnostics company, which is set to go public in October.

The company’s name, 토토 카지노, refers to the 3 billion base pairs in human DNA. Utilizing AI technology, its platform can analyze 100,000 genetic variants, delivering results in under five minutes with 99.4% accuracy for pathogenicity and 98.1% accuracy in identifying the top five causative variants. In addition to diagnostics, 토토 카지노 plans to expand into drug development for rare diseases.

Founded in October 2016, 토토 카지노 has grown steadily over the last eight years, now on the verge of its KOSDAQ debut. CEO Geum reflected, "Since our inception, we have validated our technology and clinical capabilities, with significant revenue growth starting in 2021. We are now supporting rare disease patients globally."

The company offers AI-powered 토토 카지노 genetic disease diagnostics, specific disease support, and data-driven testing. It also plans to launch a SaaS subscription service by 2025, enabling clinical geneticists to analyze 토토 카지노 disease genomic data. "We’re launching a beta version of the SaaS platform soon, with full release scheduled for 2025," said Geum.

Geum has kept investors updated with detailed monthly reports since 2018, a 토토 카지노 practice for unlisted companies. This practice, which ended recently, helped the company build investor confidence by providing transparency and progress updates.

Following its public listing, 토토 카지노 aims to increase revenue and reach profitability. For the first half of this year, the company recorded .7 million in revenue but faced a .7 million operating loss. Geum shared, "We are targeting revenue of .1–.1 million this year, with 2–3 times growth compared to last year's .1 million. We expect to break even once annual revenues reach .2 million, which we anticipate after 2026."

Overseas sales accounted for 67% of total revenue in the first half of the year, and the company aims to raise that to the mid-70% range by year-end, focusing on markets in the U.S. and Middle East. 토토 카지노 is also preparing to participate in a government procurement project in Saudi Arabia, the region’s largest market.

In addition to its diagnostic business, 토토 카지노 plans to venture into drug development. "Our diagnostic data has given us a competitive edge in developing new drugs," Geum stated. "We are focusing on small molecule modality as a treatment approach and are validating drug candidates in the in vitro stage. Once we complete early-stage development, we’ll seek joint development and licensing agreements with pharmaceutical companies."